Urea cycle disorders (UCDs) — NAGS / CPS1 / OTC (X-linked) / citrullinemia type 1 + 2 / argininosuccinic aciduria / argininemia / HHH

What changes during this transition

Urea cycle disorders arrive in the peptide-companion library along four predictable community-curiosity vectors, each of which fails on the same load-bearing reality: this is a Mendelian disorder of nitrogen handling with a hyperammonemic-encephalopathy mortality axis, a mature pharmacologic toolkit (ammonia scavengers, cofactor replacement, amino acid supplementation, lifelong protein-restricted diet), liver transplantation as a definitive option for severe forms, and an AAV/mRNA gene-therapy frontier already in late-phase trials — and peptides do not address any of the load-bearing axes. Ornithine transcarbamylase (OTC) deficiency is the most common UCD at roughly half of all cases and is X-linked, which produces an editorially distinct picture: males present severely in the neonatal period, and females present variably depending on X-inactivation skew — from severe early presentations through milder partial forms to asymptomatic carriers who can decompensate in pregnancy, the postpartum period, after surgery, or with intercurrent illness. This female OTC heterozygote cohort is a real population, and they are exactly the adults who arrive at general-aging, GLP-1, and GH-axis peptide conversations and who require careful coordination with the metabolic team before any layered intervention. The other distinct adult cohort is citrullinemia type II (CTLN2, SLC25A13 citrin transporter deficiency), with adult-onset presentation and Japanese predominance — chronic liver involvement carries hepatocellular carcinoma risk on top of the metabolic picture. Newborn screening on the US RUSP detects citrullinemia, argininosuccinic aciduria, and arginase deficiency. OTC and CPS1, however, are NOT detected by newborn screening — there is no diagnostic acylcarnitine signature, and diagnosis happens post-presentation, often after the first hyperammonemic crisis. This diagnostic-delay-until-crisis pattern is the editorially load-bearing fact for OTC and CPS1, and the neonatal classic presentation (lethargy + vomiting + hyperventilation, progressing to coma and cerebral edema within hours to days) is the most pediatric-editorially-sensitive presentation in the entire batch. Standard-of-care management is mature: AMMONUL FDA 2005 IV scavenger; BUPHENYL FDA 1996 oral chronic; RAVICTI FDA February 2013 improved-palatability liquid transformative for chronic adherence; CARBAGLU FDA 2010 for NAGS deficiency; CITRULLINE for CPS1/OTC; ARGININE for ASS1/ASL; lifelong protein-restricted diet on medical foods; LIVER TRANSPLANTATION as definitive therapy for severe forms; gene-therapy frontier DTX301 Phase 3 ASCEND + ARCT-810 Phase 2. The peptide library does not earn elevation. BPC-157's pro-angiogenic framing reaches UCD patients sideways with no characterization. NMN's general-aging framing reaches the aging female OTC heterozygote cohort. The GH-axis trio carries the sharpest mechanism-vs-disease concern: GH and IGF-1 anabolism drive nitrogen flux and ammonia load, which is exactly the variable the lifelong protein-restricted diet, ammonia scavenger dosing, and citrulline/arginine supplementation are built to control. Tesamorelin's HIV-LD FDA label does NOT propagate to UCD (Rule 6 non-propagation sharp). Semaglutide reaches adult UCD with appetite suppression interfering with the medical-food protein-substitute regimen plus catabolic ammonia load risk during GI illness or titration. Ninety-eighth deliberate non-elevation.